To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
119th Congress
HR 679 nullifies recent FDA changes to mifepristone's risk evaluation strategy, limiting HHS's authority and potentially impacting access to medical abortion services.
Introduced in House
